+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

RPEL proteins are the molecular targets for CCG-1423, an inhibitor of Rho signaling

RPEL proteins are the molecular targets for CCG-1423, an inhibitor of Rho signaling

Plos One 9(2): E89016-E89016

Epithelial-msenchymal transition (EMT) is closely associated with cancer and tissue fibrosis. The nuclear accumulation of myocardin-related transcription factor A (MRTF-A/MAL/MKL1) plays a vital role in EMT. In various cells treated with CCG-1423, a novel inhibitor of Rho signaling, the nuclear accumulation of MRTF-A is inhibited. However, the molecular target of this inhibitor has not yet been identified. In this study, we investigated the mechanism of this effect of CCG-1423. The interaction between MRTF-A and importin α/β1 was inhibited by CCG-1423, but monomeric G-actin binding to MRTF-A was not inhibited. We coupled Sepharose with CCG-1423 (CCG-1423 Sepharose) to investigate this mechanism. A pull-down assay using CCG-1423 Sepharose revealed the direct binding of CCG-1423 to MRTF-A. Furthermore, we found that the N-terminal basic domain (NB) of MRTF-A, which acts as a functional nuclear localization signal (NLS) of MRTF-A, was the binding site for CCG-1423. G-actin did not bind to CCG-1423 Sepharose, but the interaction between MRTF-A and CCG-1423 Sepharose was reduced in the presence of G-actin. We attribute this result to the high binding affinity of MRTF-A for G-actin and the proximity of NB to G-actin-binding sites (RPEL motifs). Therefore, when MRTF-A forms a complex with G-actin, the binding of CCG-1423 to NB is expected to be blocked. NF-E2 related factor 2, which contains three distinct basic amino acid-rich NLSs, did not bind to CCG-1423 Sepharose, but other RPEL-containing proteins such as MRTF-B, myocardin, and Phactr1 bound to CCG-1423 Sepharose. These results suggest that the specific binding of CCG-1423 to the NLSs of RPEL-containing proteins. Our proposal to explain the inhibitory action of CCG-1423 is as follows: When the G-actin pool is depleted, CCG-1423 binds specifically to the NLS of MRTF-A/B and prevents the interaction between MRTF-A/B and importin α/β1, resulting in inhibition of the nuclear import of MRTF-A/B.

(PDF same-day service: $19.90)

Accession: 055338577

Download citation: RISBibTeXText

PMID: 24558465

DOI: 10.1371/journal.pone.0089016

Related references

Design and synthesis of tag-free photoprobes for the identification of the molecular target for CCG-1423, a novel inhibitor of the Rho/MKL1/SRF signaling pathway. Beilstein Journal of Organic Chemistry 9: 966-973, 2013

Structures of the Phactr1 RPEL domain and RPEL motif complexes with G-actin reveal the molecular basis for actin binding cooperativity. Structure 20(11): 1960-1970, 2013

CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Molecular Cancer Therapeutics 6(8): 2249-2260, 2007

The inhibitor of apoptosis (IAP) proteins are critical regulators of signaling pathways and targets for anti-cancer therapy. Experimental Oncology 34(3): 200-211, 2013

Molecular cloning of pancreatic islet winged helix proteins Candidates for targets of insulin signaling. Naunyn-Schmiedeberg's Archives of Pharmacology 357(4 SUPPL): R83, 1998

Heat shock proteins in cancer: signaling pathways, tumor markers and molecular targets in liver malignancy. Protein and Peptide Letters 16(5): 508-516, 2009

RPEL motifs link the serum response factor cofactor MAL but not myocardin to Rho signaling via actin binding. Molecular and Cellular Biology 28(2): 732-742, 2007

Overexpression of a family of RPEL proteins modifies cell shape. Febs Letters 579(1): 100-104, 2004

Signaling proteins as innovative targets for antineoplastic therapy: our experience with the signaling protein c-myc. Tumori 87(6): S20-S23, 2002

RPEL family proteins: transcriptional co-activators and mediators for actin-based structural alteration. Seikagaku. Journal of Japanese Biochemical Society 78(10): 987-997, 2006

Ras signaling pathway proteins as therapeutic targets. Current Pharmaceutical Design 7(16): 1581-1594, 2001

A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of Ras. Oncotarget 6(7): 5382-5411, 2016

Fangchinoline as a kinase inhibitor targets FAK and suppresses FAK-mediated signaling pathway in A549. Journal of Drug Targeting 23(3): 266-274, 2016

Design, synthesis and prostate cancer cell-based studies of analogs of the Rho/MKL1 transcriptional pathway inhibitor, CCG-1423. Bioorganic & Medicinal Chemistry Letters 20(2): 665-672, 2010

Molecular interaction of a kinase inhibitor midostaurin with anticancer drug targets, S100A8 and EGFR: transcriptional profiling and molecular docking study for kidney cancer therapeutics. Plos One 10(3): E0119765-E0119765, 2016